Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle

Related Experiment Videos

K T Tan1, M H Tayebjee, H S Lim

  • 1Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine City Hospital, Birmingham, UK.

Diabetic Medicine : a Journal of the British Diabetic Association
|January 13, 2006
PubMed
Abstract

Insights

Platelet microparticles (PMPs) are elevated in Type 2 diabetes, particularly in those with atherosclerosis. These PMPs may serve as a marker for vascular disease and a target for anti-thrombotic therapies.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Hematology

Background:

  • Atherothrombosis is a leading cause of mortality in Type 2 diabetes, linked to coagulation, fibrinolysis, and platelet function abnormalities.
  • Platelet microparticles (PMPs) may exacerbate the prothrombotic state and accelerate atherosclerosis.
  • Elevated PMPs are hypothesized in Type 2 diabetes, with the highest levels expected in patients with clinically evident atherosclerosis.

Purpose of the Study:

  • To investigate PMP levels in Type 2 diabetic patients with and without atherosclerosis.
  • To assess soluble plasma P-selectin (sPsel) and CD40L, and platelet surface markers (%CD62P, %CD63) in these groups.
  • To determine correlations between PMPs and other platelet activation markers.

Main Methods:

  • Flow cytometry was used to quantify PMPs, %CD62P, and %CD63 on platelets.
  • ELISA was employed to measure sPsel and CD40L levels.
  • Study included 21 Type 2 diabetic patients without atherosclerosis, 18 with atherosclerosis, and 21 non-diabetic controls.

Main Results:

  • Patients with Type 2 diabetes and atherosclerosis exhibited significantly higher PMP and sPsel levels compared to those without complications and controls.
  • Control subjects had the lowest CD40L levels; no significant difference was found between diabetic subgroups.
  • %CD62P and %CD63 positivity did not vary across groups.
  • PMP levels correlated with %CD62P positivity but not with other measured markers.

Conclusions:

  • PMPs are elevated in Type 2 diabetes, with markedly higher levels in those with symptomatic atherosclerotic vascular disease.
  • PMPs may serve as a valuable biomarker for risk stratification in Type 2 diabetes.
  • PMPs represent a potential therapeutic target for novel anti-thrombotic drugs in diabetic patients.

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...